Veeva Systems today announced that Alcon, a global medical device company specializing in surgical and vision care products, chose Veeva Vault Clinical Data Management System (CDMS) as its enterprise clinical data management system for electronic data capture (EDC).
Veeva Vault CDMS is a suite of clinical data management applications on a single cloud platform that enables Alcon to manage studies from build through execution in an integrated way. Vault EDC, part of Vault CDMS, provides an intuitive interface for capturing trial data and is designed for flexibility so Alcon can create study builds faster and make mid-study changes with no downtime.
As a newly independent company, Alcon had the opportunity to select modern applications that support its ambitious R&D program. Vault CDMS meets the specific requirements and fast development cycles of medical device research while adding efficiencies in trial data management.
“Rapid study startups are crucial for us because of the quick development cycles of medical device products,” said Lisa Sauls, R&D IT director, clinical and regulatory affairs, at Alcon. “Veeva Vault CDMS is an innovative, high quality solution that offers speed and the flexibility to accommodate medical device data.”
“Veeva Vault CDMS helps life sciences companies improve agility in data management and efficiency from startup through completion,” said Henry Levy, general manager, Veeva Vault CDMS. “With its move to Veeva Vault, Alcon has the foundation to speed innovation in eye care.”
In addition to Vault CDMS, Alcon is adopting Vault PromoMats, Vault eTMF, Vault CTMS, Vault Submissions, Vault Submissions Archive, Vault QualityDocs, and Vault Training.
To see how Vault CDMS helps companies cut their EDC study build times by 40-60%, register for the upcoming webinar on Tuesday, July 16, 2019.
Alcon (alcon.com) helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, Alcon offer the broadest portfolio of products to enhance sight and improve people’s lives. Based in Geneva, Switzerland, and Fort Worth, Texas, the company’s surgical and vision care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. More than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care.
About Veeva Systems
Veeva Systems, Inc. (veeva.com) is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 750 customers, ranging from the world’s largest pharmaceutical and medical device companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions,“Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.